Background: Cancer is a non-communicable disease with increasing incidence and mortality rates worldwide, including Thailand. Its apparent lack of effective treatments is posing challenging public health issues.

Introduction: Encouraging research results indicating probable anti-cancer properties of the Delonix regia flower Extract (DRE) have prompted us to evaluate the feasibility of developing a type of product for future cancer prevention or treatment.

Methods and Results: In the present report, using High-Performance Liquid Chromatography (HPLC), we demonstrate in the DRE the presence of high concentrations of three identifiable flavonoids, namely rutin 4.15±0.30% w/w, isoquercitrin 3.04±0.02 %w/w, and myricetin 2.61±0.01% w/w, respectively, while the IC50 of DPPH and ABTS assay antioxidation activity was 66.88±6.30 μg/ml and 53.65±7.24 μg/ml, respectively.

Discussion: Our cancer cell line studies using the MTT assay demonstrated DREs potent and dosedependent inhibition of murine leukemia cell line (P-388: 35.28±4.07% of cell viability remaining), as well as of human breast adenocarcinoma (MCF-7), human cervical carcinoma (HeLa), human oral cavity carcinoma (KB), and human colon carcinoma (HT-29) cell lines in that order of magnitude.

Conclusion: Three identifiable flavonoids (rutin, isoquercitrin and myricetin) with high antioxidation activity and potent and dose-dependent inhibition of murine leukemia cell line and five other cancer cell lines were documented in the DRE. The extract’s lack of cytotoxicity in 3 normal cell lines is a rare advantage not usually seen in current antineoplastic agents. Yet another challenge of the DRE was its low dissolution rate and long-term storage stability, issues to be resolved before a future product can be formulated.

背景：癌症是一种非传染性疾病，其发病率和死亡率在世界范围内不断增加，包括泰国。其明显缺乏有效的治疗方法正在构成具有挑战性的公共卫生问题。

简介：令人鼓舞的研究结果表明，帝王花提取物 (DRE) 可能具有抗癌特性，这促使我们评估开发一种用于未来癌症预防或治疗的产品的可行性。

方法和结果：在本报告中，我们使用高效液相色谱 (HPLC) 证明了 DRE 中存在高浓度的三种可识别的黄酮类化合物，即芦丁 4.15±0.30% w/w、异槲皮苷 3.04±0.02 %w /w 和杨梅素分别为 2.61±0.01% w/w，而 DPPH 和 ABTS 测定抗氧化活性的 IC50 分别为 66.88±6.30 μg/ml 和 53.65±7.24 μg/ml。

讨论：我们使用 MTT 分析的癌细胞系研究表明，DRE 对鼠白血病细胞系（P-388：剩余细胞活力的 35.28±4.07%）以及人乳腺癌（MCF-7）具有强效和剂量依赖性抑制作用，人类宫颈癌 (HeLa)、人类口腔癌 (KB) 和人类结肠癌 (HT-29) 细胞系。

结论：在 DRE 中记录了三种可识别的黄酮类化合物（芦丁、异槲皮苷和杨梅素），它们具有高抗氧化活性以及对鼠白血病细胞系和其他五种癌细胞系的强效和剂量依赖性抑制。该提取物在 3 种正常细胞系中没有细胞毒性，这是一个罕见的优势，在目前的抗肿瘤药物中并不常见。DRE 的另一个挑战是其低溶出率和长期储存稳定性，这些问题需要在未来产品配制之前解决。